+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Registry of neuroendocrine tumors (NET) in Czech Republic after three years of data collection



Registry of neuroendocrine tumors (NET) in Czech Republic after three years of data collection



Klinicka Onkologie 26(4): 271-280



Neuroendocrine tumors are traditionally considered to be "rare" diseases. On contrary, the prevalence of neuroendocrine tumors is high. Therefore, the diagnostics, treatment and follow-up of neuroendocrine tumors are subjected to an evolving interest. There are various specifics of neuroendocrine tumors requiring an appropriate feedback of each intervention i.e. data collection and central data evaluation. The "Cooperative Group for Neuroendocrine Tumors" (KSPNN) has been conducting a nationwide neuroendocrine tumors registry since June 2009. The first data summary after three years is aimed at evaluation of feasibility and data utility. The anonymous data on diagnostics, therapy and follow up of patients with neuroendocrine tumors of any primary site are collected in the registry. The contribution is conditioned by morphologically proven diagnosis according to the current WHO 2010 classification, in earlier cases WHO 2000 classification. The registry is operated by the Institute of Biostatistics and Analyses, Masaryk University (Brno). The initial analysis includes data from June 2009 to October 2012. Data of a substantial share of neuroendocrine tumor carriers have been collected -  742 subjects with a valid record, i.e. about 14% of presumed prevalence. Moreover, the registry covers nearly one fourth of incidence in the period 2009- 2011. The morphological diagnoses with the sign of nonspecific "neuroendocrine tumors" comprise the majority of records (75%); the most frequent is "carcinoid tumor neuroendocrine tumors". This results in a clear requirement for more detailed specifications of morphology as well as separation of small cell (neuroendocrine) carcinoma possessing principal bio-logic differences to neuroendocrine tumors itself. There is an apparent polarity of recorded clinical stages. Both stage I and stage IV comprise 30% of the records. This result is presumably related to how the diagnosis is established, either early and incidentally in initial stage or late with a developed endocrine symptomatology, in advanced stage. There is an evident selection bias. The treatment data reflect current trends, dominance of surgical therapy including reasonable cytoreductive surgery, vast use of somatostatine analogues in advanced disease and persistent position of chemotherapy for high grade tumors. The distribution of treatment modalities in the records documents a certain adherence to international treatment standards (ENETS, ESMO, NCCN). The dynamics of data contributions confirm feasibility of data collection in the registry. The registry reveals a clear requirement for more detailed analyses of biopsies and more detailed disease morphology classification. In the near future, the registry is aimed to maintain the increasing volume of collected data and to cover the majority of neuroendocrine tumors incidence.

(PDF emailed within 1 workday: $29.90)

Accession: 055446542

Download citation: RISBibTeXText

PMID: 23961858


Related references

Data collection and the Czech Republic Trauma Registry. Rozhledy V Chirurgii 85(10): 504-507, 2007

Evaluation of the development of laparoscopically-assisted vaginal hysterectomy in the Czech Republic over the last 10 years based on the data of the National Registry of Gynecology Laparoscopy Complications. Ceska Gynekologie 72(2): 109-112, 2007

Myotonic dystrophy in Czech Republic: data from the national registry. Journal of the Neurological Sciences 357: E347-E348, 2015

National Registry of Congenital Anomalies of the Czech Republic: commemorating 50 years of the official registration. Central European Journal of Public Health 22(4): 287-288, 2015

Czech registry of complications in gynecological laparoscopy - the on-line data collection. Ceska Gynekologie 79(1): 53-56, 2015

AB0327Abatacept and its use in the treatment of rheumatoid arthritis (ra) in the czech republic data from the attra registry. Annals of the Rheumatic Diseases 72(Suppl 3): A887.2-A887, 2013

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clinical Rheumatology 32(10): 1451-1458, 2014

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation. Klinicka Onkologie 30(Supplementum2): 43-50, 2017

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 15(3): 752-759, 2010

Pharmacotherapy in patients after acute myocardial infarction - the basis for effective secondary prevention. Data from a pilot registry in the Czech republic. 2007

Tumors in children with birth defects. Current data from the Czech Republic. Ceska Gynekologie 74(2): 105-117, 2009

Preliminary report of data collection in hospital quality assurance programs--a project of the Association of Hospitals of the Czech Republic. International Journal for Quality in Health Care 8(6): 577-582, 1996

Contribution of the Dijon Stroke Registry after 20 years of data collection. Revue Neurologique 164(2): 138-147, 2008

Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry. Indian Journal of Gastroenterology, 2018

Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic. Vnitrni Lekarstvi 64(4): 357-366, 2018